[go: up one dir, main page]

EA200300628A1 - CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their Use - Google Patents

CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their Use

Info

Publication number
EA200300628A1
EA200300628A1 EA200300628A EA200300628A EA200300628A1 EA 200300628 A1 EA200300628 A1 EA 200300628A1 EA 200300628 A EA200300628 A EA 200300628A EA 200300628 A EA200300628 A EA 200300628A EA 200300628 A1 EA200300628 A1 EA 200300628A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adenosine
arecceptor
compounds
connections specific
receptors
Prior art date
Application number
EA200300628A
Other languages
Russian (ru)
Other versions
EA007254B1 (en
Inventor
Арлиндо Л. Кастэлано
Брайан МакКиббен
Дэвид Дж. Уиттер
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of EA200300628A1 publication Critical patent/EA200300628A1/en
Publication of EA007254B1 publication Critical patent/EA007254B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к соединениям, которые специфически ингибируют A, Aи Aрецепторы, и применению данных соединений для лечения заболеваний, связанных с A, Aи Aаденозиновыми рецепторами, у субъектов, включающему введение субъекту терапевтически эффективного количества соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to compounds that specifically inhibit A, A, and A receptors, and the use of these compounds to treat diseases associated with A, A, and Adenosine receptors in subjects, including administering to the subject a therapeutically effective amount of compounds. The international application has been published search.

EA200300628A 2000-12-01 2001-11-30 Compounds specific to adenosine a, aand areceptor and uses thereof EA007254B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (2)

Publication Number Publication Date
EA200300628A1 true EA200300628A1 (en) 2003-12-25
EA007254B1 EA007254B1 (en) 2006-08-25

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300628A EA007254B1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a, aand areceptor and uses thereof

Country Status (20)

Country Link
EP (1) EP1347980A4 (en)
JP (1) JP4579497B2 (en)
CN (1) CN1263757C (en)
AP (1) AP1893A (en)
AU (1) AU2002248151B2 (en)
BR (1) BR0115847A (en)
CA (1) CA2430577A1 (en)
CZ (1) CZ20031831A3 (en)
EA (1) EA007254B1 (en)
HU (1) HUP0400692A3 (en)
IL (1) IL155962A0 (en)
ME (1) MEP35308A (en)
MX (1) MXPA03004717A (en)
NO (1) NO327207B1 (en)
NZ (1) NZ525885A (en)
OA (1) OA13295A (en)
PL (1) PL363245A1 (en)
WO (1) WO2002057267A1 (en)
YU (1) YU42703A (en)
ZA (1) ZA200303729B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
PL204628B1 (en) 1998-06-02 2010-01-29 Osi Pharmaceuticals PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) * 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
CA2468673C (en) * 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof
DE60236322D1 (en) * 2001-12-07 2010-06-17 Vertex Pharma PYRIMIDIN-BASED COMPOUNDS AS A GSK-3 HEMMER
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
DE60235500D1 (en) 2001-12-20 2010-04-08 Osi Pharm Inc SELECTIVE PYRIMIDINE A2B ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
AU2003270701B2 (en) * 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (en) 2004-10-25 2006-05-31 Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101119718B (en) * 2005-02-18 2011-06-15 索尔瓦药物有限公司 Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
ES2522365T3 (en) 2007-10-11 2014-11-14 Astrazeneca Ab Pyrrolo [2,3-D] pyrimidine derivatives as protein kinase B inhibitors
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
MY169449A (en) 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment
US20140329786A1 (en) 2011-11-30 2014-11-06 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CA2873723A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (en) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CN107207474B (en) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
HUE064003T2 (en) 2015-01-20 2024-02-28 Wuxi Fortune Pharmaceutical Co Ltd Jak inhibitor
ES2734048T3 (en) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Janus kinase inhibitors (JAK)
MX381994B (en) 2015-05-29 2025-03-13 Wuxi Fortune Pharmaceutical Co Ltd JANUS KINASE INHIBITOR.
CN105771672B (en) * 2016-04-18 2018-03-02 天津工业大学 A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
CN108570054B (en) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN108017584B (en) * 2017-06-20 2021-03-23 南开大学 A3Small molecule antagonists of adenosine receptors
CN112533923B (en) * 2018-06-04 2024-07-09 爱克思科技有限公司 Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) * 2019-05-22 2021-08-31 北京大学深圳研究生院 The preparation method of 5-substituted β-proline and its derivatives
CN110272373B (en) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
PL204628B1 (en) * 1998-06-02 2010-01-29 Osi Pharmaceuticals PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
DK1246623T3 (en) * 1999-12-02 2006-11-13 Osi Pharm Inc Compounds specific for adenosine A1, A2a, and A3 receptor and uses thereof
CA2468673C (en) * 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof

Also Published As

Publication number Publication date
ZA200303729B (en) 2004-05-14
MXPA03004717A (en) 2004-06-30
JP4579497B2 (en) 2010-11-10
MEP35308A (en) 2011-02-10
EP1347980A4 (en) 2005-02-09
AP2003002807A0 (en) 2003-06-30
NO327207B1 (en) 2009-05-11
HUP0400692A2 (en) 2004-07-28
JP2004517896A (en) 2004-06-17
EP1347980A1 (en) 2003-10-01
CN1489590A (en) 2004-04-14
AP1893A (en) 2008-09-23
PL363245A1 (en) 2004-11-15
NZ525885A (en) 2005-01-28
NO20032482L (en) 2003-07-28
EA007254B1 (en) 2006-08-25
BR0115847A (en) 2004-02-25
HUP0400692A3 (en) 2007-09-28
YU42703A (en) 2006-03-03
CN1263757C (en) 2006-07-12
AU2002248151B2 (en) 2008-02-21
OA13295A (en) 2007-04-13
NO20032482D0 (en) 2003-06-02
IL155962A0 (en) 2003-12-23
CZ20031831A3 (en) 2004-05-12
WO2002057267A1 (en) 2002-07-25
CA2430577A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
EA200300628A1 (en) CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their Use
EA200100780A1 (en) TWEAK ANTAGONISTS AND TWEAK RECEPTORS AND THEIR USE FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES
DK1450811T3 (en) Compounds specific for adenosine A1 and A3 receptors and uses thereof
WO2001039777A8 (en) Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
EA200300293A1 (en) ANTI-INFLAMMATORY CONDENSED Pyrrolocarbazoles
CY1118429T1 (en) ALPHA4VETA7 INTEGRINE CONNECTION ANTIBODY AND ITS USE IN THERAPEUTIC DISEASE
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
CY1105082T1 (en) USE OF FLIVANSEPIN IN THE TREATMENT OF SEXUAL DESIRE DISORDERS
EA200500520A1 (en) PURINE COMPOUNDS AND THEIR APPLICATION AS CANCELINOID RECEPTOR LIGANDS AS LIGANDS
EA200601776A1 (en) METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION
CY1112858T1 (en) THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONE ANTIBODY
TR200103233T2 (en) New drug compositions on the basis of anticholinergic compounds and ß-mimetics.
BG66080B1 (en) Substituted thioacetamides
EA200200616A1 (en) CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
ATE371645T1 (en) NAPHTHALINE DERIVATIVES THAT BIND TO THE EP4 RECEPTOR
ES2166111T3 (en) USE OF TIAGABINE FOR THE TREATMENT OF SLEEP DISORDERS.
CY1106845T1 (en) USE OF FLUMAZENIL FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF COCAINE DEPENDENCE
CY1108430T1 (en) USE OF NETHERLANDS SIDE BASKET COMPETITORS WITH AMITERASE FOR ECOPARATOMETER CONTROLS IN HOUSEHOLD ANIMALS
EA200401341A1 (en) APPLICATION OF OSTEOPROTEGERIN FOR THE TREATMENT AND / OR PREVENTION OF FIBROUS DISEASE
EA200400689A1 (en) PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING AROMATIC ALDEHYDES CONTAINING OXYGROUP
EE200200107A (en) Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction
BRPI0409359A (en) somatostatin-dopamine chimeric analogs
TR199802769T2 (en) Topical composition containing a combination of terpenoid compounds and antihistamine compounds.
TR200001040T2 (en) A new use of compounds for an anti-itch effect
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU